SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (793)4/23/2003 5:39:24 PM
From: Madharry  Respond to of 3559
 
Well I spent a few minutes reviewing some of the filings- that convertible offering is some piece of work. it is specifically designated to be a subordinated debt- subordinated to all existing and future senior debt.
There was also mention that under certain conditions the company can redeem the bonds at maturity with shares.
Also the this company has class A stock which has 10 times the voting power of ordinary stock. Good luck!



To: keokalani'nui who wrote (793)4/23/2003 7:07:36 PM
From: Miljenko Zuanic  Read Replies (2) | Respond to of 3559
 
WE,

REGN made many mistakes and CV is one of them. But, not the biggest one. There is way out, IF they STOP making mistakes.

Regards the IL-1 Trap, it is OA that hold interesting opportunity for their collaborations. Unfortunately, at this moment we do not know how is this option incorporated in deal. Also, Pralnacasan PIIa may help clearing fog on window.

Miljenko


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News